New predictive test to improve cancer survival


Berlin – Survival rates from colorectal cancer (CRC) differ dramatically according to the stage of the tumor at diagnosis, with survival rates of 90% for patients with stage I disease but only 49% for those with stage III cancer. German researchers now have presented clinical validation data for a revolutionary early biomarker, which allows to recognize if subjects with colorectal carcinoma (CRC) are at high risk to develop fatal metastases or not. „Our correct prediction on whether a subject with colon cancer will develop distant metastases over a period of 10 years, was correct for 78 % of subjects with stage I to III CRC, which expressed MACC1 mRNA at a low level“, lead investigator Ulrike Stein (Max-Delbruck-Center, Berlin) told EuroBiotechNews at the BioTOP Agenda meeting in Berlin. Stein, who has patented MACC1 in 2003 and is awaiting approval this year, is in talks with several companies after initial findings were published in Nature Medicine (doi 10.1038/nm.1889). „Our goal is to develop a quantitative PCR test that predicts the risk of cancer recurrence based on expression of the biomarker MACC1. In Berlin, the group invited the industry to participate in the commercialisation of the findings.
Further data show that patients, who expressed low levels of MACC1, showed 5-year survival rates of 80%, but only 15% for subjects with high MACC1 level. Expression of the MACC1 protein induced cell migration by more than 5-fold, invasion and colony formation by factor
Preclincal analyses of the MACC1 protein, which carries motifs characteristic for tyrosine kinases, and CHiP analyses suggest that MACC1 is a transcriptional regulator of MET, the gene encoding the receptor for the hepatocate growth factor (HGF), which is a target for several cancer drug candidates. Whether the biomarker is also an attractive drug target has to be demonstrated in clinical trials.



Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...



Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...



Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...



Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...



Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...



Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...



Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...



Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....



Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



All Events

Stock list

All quotes


  • NORDIC NANOVECTOR (N)24.00 NOK23.71%
  • TRANSGENE (F)4.72 EUR23.56%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%


  • THROMBOGENICS (B)3.09 EUR-20.97%
  • ZELTIA (E)3.35 EUR-12.76%
  • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%


  • KARO BIO (S)38.50 SEK2383.9%
  • TRANSGENE (F)4.72 EUR63.9%


  • THROMBOGENICS (B)3.09 EUR-42.4%
  • WILEX (D)2.05 EUR-41.4%
  • BIONOR PHARMA (N)1.26 NOK-39.4%


  • KARO BIO (S)38.50 SEK4595.1%
  • ADOCIA (F)87.65 EUR439.1%
  • GALAPAGOS (B)54.02 EUR324.7%


  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.84 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015

Current issue

All issues